绿叶制药(02186)下跌2.12%，报3.69元/股

Group 1 - The core point of the article highlights the recent stock performance of Green Leaf Pharmaceutical, which saw a decline of 2.12% to 3.69 CNY per share with a trading volume of 304 million CNY [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, with a product portfolio of over 30 products available in more than 80 countries and regions [1] - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1] Group 2 - The company is set to disclose its interim report for the fiscal year 2025 on August 28 [1]